Ally Bridge, a global healthcare investment management firm, led a $10m series A funding round in Alzheon, an American clinical-stage biopharmaceutical company. "With our advanced amyloid-targeting ALZ-801 clinical candidate, we are well-positioned in the dynamic field of drug candidates for Alzheimer's disease. The excitement in our company was reflected in the strong interest we have received for our Series A fundraising, which we designed to support our plans to initiate a pivotal study of ALZ-801 in Alzheimer's disease," Martin Tolar, Alzheon Founder, President and CEO.